Integrating Genomics into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead

Anjana Pillai*, Joseph Ahn, Laura Kulik

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


The incidence and mortality related to hepatocellular carcinoma (HCC) continue to increase in the United States, with most patients presenting at advanced stages where curative therapy and long-term survival is unlikely. Fortunately, significant progress has been made in identifying the landscape of HCC mutations due to advances in whole genome expression profiling. Drug development has also evolved in recent years with multiple first- and second-line systemic chemotherapy agents approved for HCC for the first time in over a decade. However, despite advances in molecular profiling, mutations that were identified at the highest frequency were not amenable to drug development, and curative therapy for advanced HCC remains elusive. This review focuses on the current understanding of HCC genomics and the limitations of translating the current HCC molecular profiling into clinical practice and examines the effectiveness and benefits of approved systemic therapies for advanced HCC.

Original languageEnglish (US)
Pages (from-to)1960-1969
Number of pages10
JournalAmerican Journal of Gastroenterology
Issue number12
StatePublished - Dec 1 2020

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Integrating Genomics into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead'. Together they form a unique fingerprint.

Cite this